Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening

Anti-Cancer Drugs

Volumn 26, Issue 4, 2015, Pages 437-442

  Trelinska, Joanna ^a   Dachowska, Iwona ^a   Kotulska, Katarzyna ^b   Fendler, Wojciech ^a   Jozwiak, Sergiusz ^b   Mlynarski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

adverse events; everolimus; mammalian target of rapamycin inhibitor; subependymal giant cell astrocytoma; tuberous sclerosis

Indexed keywords

C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; EVEROLIMUS; GLUCOSE; HEMOGLOBIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BLOOD CELL COUNT; BLOOD CULTURE; BRONCHITIS; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; ESCHERICHIA COLI; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFANT; INFECTION COMPLICATION; INTENSIVE CARE UNIT; KIDNEY FUNCTION TEST; KIDNEY HEMANGIOMYOLIPOMA; LEUKOPENIA; LIVER FUNCTION TEST; MALE; MINIMUM PLASMA CONCENTRATION; NEUTROPENIA; OLIGOMENORRHEA; OVARY CYST; PATIENT TRANSPORT; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMATITIS; STREPTOCOCCUS PNEUMONIA; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TREATMENT DURATION; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX; URINE CULTURE; ANALOGS AND DERIVATIVES; ANGIOMYOLIPOMA; ANTAGONISTS AND INHIBITORS; CASE REPORT; GLIOMA, SUBEPENDYMAL; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANGIOMYOLIPOMA; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; GLIOMA, SUBEPENDYMAL; HUMANS; INFANT; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84924855415     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000207     Document Type: Article

References (20)

1. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer and transplantation. Am J Transplant 2008; 8:2212-2218.
2. Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation: reviewing the evidence. J Transplant 2014; 2014:845438.
3. Russ GR. Optimising the use of mTOR inhibitors in renal transplantation. Transplant Res 2013; 2 (Suppl 1):S4.
4. Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013; 1291:14-32.
5. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125-132.
6. Lyczkowski DA, Conant KD, Pulsifer MB, Jarrett DY, Grant PE, Kwiatkowski DJ, Thiele EA. Intrafamilial phenotypic variability in tuberous sclerosis complex. J Child Neurol 2007; 22:1348-1355.
7. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817-824.
8. Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 2014; 28:126-133.
9. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13:624-628.
10. Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:243-254.
11. Tszyrsznic W, Borowiec A, Pawlowska E, Jazwiec R, Zochowska D, Bartlomiejczyk I, et al. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 928:9-15.
12. National Cancer Institute. Common Terminology Criteria for Adverse Events v40. NCI, NIH, DHHS; 2009. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. [Accessed 31 May 2014].
13. Motzer RJ, Escudier B, Oudard S, Huston TE, Porta C, Bracard S, et al. RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
14. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8:651-657.
15. Haneda M, Owaki M, Kuzuya T, Iwasaki K, Miwa Y, Kobayashi T. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 2014; 97:405-12.
16. San Segundo D, Fernández-Fresnedo G, Gago M, Beares I, Ruiz-Criado J, González M, et al. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. Transplant Proc 2010; 42:2871-2873.
17. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 2013; 80:574-580.
18. Roa J, Tena-Sempere M. Energy balance and puberty onset: emerging role of central mTOR signaling. Trends Endocrinol Metab 2010; 21:519-528.
19. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74:679-687.
20. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47:1287-1298.